Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Primary ipilimumab + nivolumab followed by adjuvant nivolumab in resectable melanoma
2018-002172-40Phase 2Completed
- Sponsor
- European Institute of Oncology
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in melanoma, sponsored by European Institute of Oncology. Primary endpoint: Pathological complete response rate after surgery. Started Nov 2020; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2018-002172-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002172-40.